Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 5, 1996, Pages

  Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

colorectal cancer; non comparative studies

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERFERON; NEW DRUG; OXALIPLATIN;

CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029856893     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00335-8     Document Type: Conference Paper

References (30)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1993, 43, 7-26.
2. Ziegler RG, Devesa SS, Fraumeni JF. Epidemiology pattern of colorectal cancer. In DeVita VT, Hellman S, Rosenberg SA, eds, Important Advances in Oncology 1986, Philadelphia, JB Lippincott Co., 209-232.
3. Kemeny N. Current approaches to metastatic colorectal cancer. Semin Oncol 1994, 21, Suppl 7, 67-75.
4. Moertel CG. Chemotherapy for colorectal cancer. New Engl J Med 1994, 330, 1136-1142.
5. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
6. Gastrointestinal Tumour Study Group. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1990, 8, 185-192.
7. Drewinko B, Yang LY. Cellular basis for the inefficacy of 5-fluorouracil in human cell carcinoma. Cancer Treat Rep 1985, 69, 1391-1398.
8. Diaz-Rubio E, Aranda E, Camps C, et al. A phase II study of weekly 48-hour infusions with high-dose fluorouracil in advanced colorectal cancer: an alternative to biochemical modulation. A trial of the Spanish Cooperative Group for Tumor Therapy (T.T) Gastro-intestinal. J Infusional Chemother 1994, 4, 58-61.
9. Harstrick A, Gonzales A, Hoffmann A, Schleucher N, Vanhoefer U, Rustum Y, Seeber S, Wilke H. Development and characterisation of human gastric, colon and breast carcinoma cell lines resistant to 5-FU using various clinically relevant application schedules. Proc Am Assoc Cancer Res 1995, 36, 317 (Abstract).
10. Lokich J, Ahlgren J, Gullo J, et al. A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989, 7, 425-432.
11. Weinerman B, Shah A, Fields A, et al. A randomized grid of continuous systemic infusion versus bolus therapy with 5-fluorouracil in metastatic measurable colorectal cancer. Proc Am Soc Clin Oncol 1990, 9, 198 (Abstract).
12. Hansen R, Ryan L, Anderson T, et al. A phase III trial of bolus 5FU versus protracted infusion 5FU ± cisplatin in metastatic colorectal cancer: an Eastern Co-operative Oncology Group study (Est 2286). Proc Am Soc Clin Oncol 1992, 11, 171 (Abstract).
13. Rougier PH, Pailot B, Laplanche A, et al. End results of a multicentric randomized trial comparing 5FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992, 11, 163 (Abstract).
14. Leichman CG, Fleming TR, Maggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13, 1303-1311.
15. Weh HJ, Wilke HJ, Dierlamm J, et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 28-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 1995, 5, 233-237.
16. Köhne CH, Schmoll HJ, Wilke H, et al. Weekly high dose infusional 5-fluorouracil (FU) plus leucovorin (LV) vs FU plus α-interferon (IFN) vs FU plus LV plus IFN in advanced colorectal cancer. Results of a multicenter randomized trial. Proc Am Soc Clin Oncol 1995, (Los Angeles) 194 (Abstract) No 453.
17. De Gramont A, Bosset JF, Milan C, et al. A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOL1d) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 1995, (Los Angeles) 194 (Abstract) No 455.
18. Chabner BA. Anticancer drugs. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology (4th Edition). Philadelphia, JB Lippincott Co., 1993, 325-417.
19. Schneider E, Hsiang Y-H, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990, 21, 149-183.
20. Hsiang Y-H, Lihou MG, Liu LF. Mechanism of cell killing by camptothecin: arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes. Cancer Res 1989, 49, 5077-5082.
21. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-II (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995, 31A, 1283-1287.
22. Bugat R, Rougier P, Doulliard JY, et al. Efficacy of irinotecan HCI (CPTII) in patients with metastatic colorectal cancer after progression while receiving a 5FU-based chemotherapy. Proc Am Soc Clin Oncol 1995, (Los Angeles) (Abstract) No 567.
23. Ohe Y, Sasaki Y, Shinkai T, et al. Pharmacokinetics with a 5-day continuous-infusion of a camptothecin derivative CPT-11. Proc Am Soc Clin Oncol 1991, 10, A336.
24. Chabot GG, Barilero I, Armand JP, et al. Pharmocokinetics of the camptothecin analog CPT-11 and its active metabolite SN-38 in cancer patients. Proc Am Assoc Cancer Res 1991, 32, 175 (Abstract).
25. Takeuchi S, Takamizawa H, Takeda Y, et al. An early phase II study of CPT-11 in gynecologic cancers. Gan To Kagaku Ryoho 1991, 18, 579-584.
26. Bugat R, Rougier P, Becouarn Y, et al. Irinotecan (CPT-11) is an effective agent in pretreated colorectal cancer (CRC): preliminary results of a multicentric phase II study. Ann Oncol 1995, 5(Suppl 8), 188-189.
27. Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982, 7, 401-420.
28. Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase-II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992, 69, 893-900.
29. De Gramont A. Experience of the French group GERCOD with biweekly 48-hour chemotherapy regimen in metastatic colorectal cancer. Proceedings of III Simposio Internacional de Tratamiento de Tumores Digestivos 1995 (Alicante), 41-54.
30. Levi FA, Zidani R, Di Palma M, et al. Improved therapeutic index through ambulatory circadian rhythmic delivery (CRD) of high-dose 3-drug chemotherapy in a randomized phase III multicenter trial. Proc Am Soc Clin Oncol 1994, 13, A574.